SEC Form SC 13G/A filed

2/16/21 4:28:03 PM ET

$FWP

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $FWP alert in real time by email

SC 13G/A 1 forwardpharma_13gam1dec3120.htm SC 13G/A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. 1)*

forward pharma a/s

(Name of Issuer)

AMERICAN DEPOSITARY SHARES, EACH REPRESENTING FOURTEEN ORDINARY SHARES, NOMINAL VALUE 0.01

(Title of Class of Securities)

34986J204

(CUSIP Number)

December 31, 2020

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed:

[X] Rule 13d-1(b)

[ ] Rule 13d-1(c)

[ ] Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 34986J204
(1) Names of Reporting Persons
	Newtyn Management, LLC
(2) Check the Appropriate Box if a Member of a Group (See Instructions)			(a) [ ]
			(b) [ ]

(3) SEC Use Only
(4) Citizenship or Place of Organization
	New York
Number of Shares Beneficially Owned by Each Reporting Person With:
		(5) Sole Voting Power:	0
		(6) Shared Voting Power:	0
		(7) Sole Dispositive Power:	0
		(8) Shared Dispositive Power:	0

(9) Aggregate Amount Beneficially Owned by Each Reporting Person
	0
(10) Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions):
	[ ]
(11) Percent of Class Represented by Amount in Row (9)
	0%
(12) Type of Reporting Person (See Instructions)
	IA

Item 1(a). Name of Issuer. Forward Pharma A/S (the “Company”)

Item 1(b). Address of Issuer’s Principal Executive Offices.
	Østergade 24A, 1st Floor 1100 Copenhagen K, Denmark
Item 2(a). Name of Person Filing.
	This report on Schedule 13G is being filed by Newtyn Management, LLC, a New York limited liability company. As of December 31, 2020, there are no securities owned.
Item 2(b). Address of Principal Business Office or, if None, Residence.
	The address for the Reporting Person is 60 East 42nd Street, Suite 960, New York, NY 10165.
Item 2(c). Citizenship.
	Newtyn Management, LLC is organized under the laws of the State of New York.
Item 2(d). Title of Class of Securities.
	Ordinary shares, nominal value 0.01.
Item 2(e). CUSIP No.
	34986J204

Item 3. If This Statement Is Filed Pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the Person Filing is a:
	Not Applicable.

Item 4. Ownership.

	(a) Amount Beneficially Owned:		0
	(b) Percent of Class:		0%
	(c) Number of Shares as to which the person has:
		(i) Sole power to vote or to direct the vote:	0
		(ii) Shared power to vote or to direct the vote:	0
		(iii) Sole power to dispose or to direct the disposition of:	0
		(iv) Shared power to dispose or to direct the disposition of:	0

Item 5. Ownership of Five Percent or Less of a Class.
	If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: [X]
Item 6. Ownership of More Than Five Percent on Behalf of Another Person.
	Not Applicable.
Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable.
Item 8. Identification and Classification of Members of the Group.
	Not Applicable.
Item 9. Notice of Dissolution of Group.
	Not Applicable.
Item 10. Certification.
	By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

	February 16, 2021

	NEWTYN MANAGEMENT, LLC


	By:	/s/ Eugene Dozortsev
		Name: Eugene Dozortsev
		Title: Authorized Signatory

Attention: Intentional misstatements or omissions of fact constitute

Federal criminal violations (See 18 U.S.C. 1001)

Get the next $FWP alert in real time by email

SEC Form SC 13G/A filed

2/16/21 4:28:03 PM ET

$FWP

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $FWP alert in real time by email

SC 13G/A 1 forwardpharma_13gam1dec3120.htm SC 13G/A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. 1)*

forward pharma a/s

(Name of Issuer)

AMERICAN DEPOSITARY SHARES, EACH REPRESENTING FOURTEEN ORDINARY SHARES, NOMINAL VALUE 0.01

(Title of Class of Securities)

34986J204

(CUSIP Number)

December 31, 2020

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed:

[X] Rule 13d-1(b)

[ ] Rule 13d-1(c)

[ ] Rule 13d-1(d)

CUSIP No. 34986J204
(1) Names of Reporting Persons
	Newtyn Management, LLC
(2) Check the Appropriate Box if a Member of a Group (See Instructions)			(a) [ ]
			(b) [ ]

(3) SEC Use Only
(4) Citizenship or Place of Organization
	New York
Number of Shares Beneficially Owned by Each Reporting Person With:
		(5) Sole Voting Power:	0
		(6) Shared Voting Power:	0
		(7) Sole Dispositive Power:	0
		(8) Shared Dispositive Power:	0

(9) Aggregate Amount Beneficially Owned by Each Reporting Person
	0
(10) Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions):
	[ ]
(11) Percent of Class Represented by Amount in Row (9)
	0%
(12) Type of Reporting Person (See Instructions)
	IA

Item 1(a). Name of Issuer. Forward Pharma A/S (the “Company”)

Item 1(b). Address of Issuer’s Principal Executive Offices.
	Østergade 24A, 1st Floor 1100 Copenhagen K, Denmark
Item 2(a). Name of Person Filing.
	This report on Schedule 13G is being filed by Newtyn Management, LLC, a New York limited liability company. As of December 31, 2020, there are no securities owned.
Item 2(b). Address of Principal Business Office or, if None, Residence.
	The address for the Reporting Person is 60 East 42nd Street, Suite 960, New York, NY 10165.
Item 2(c). Citizenship.
	Newtyn Management, LLC is organized under the laws of the State of New York.
Item 2(d). Title of Class of Securities.
	Ordinary shares, nominal value 0.01.
Item 2(e). CUSIP No.
	34986J204

Item 3. If This Statement Is Filed Pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the Person Filing is a:
	Not Applicable.

Item 4. Ownership.

	(a) Amount Beneficially Owned:		0
	(b) Percent of Class:		0%
	(c) Number of Shares as to which the person has:
		(i) Sole power to vote or to direct the vote:	0
		(ii) Shared power to vote or to direct the vote:	0
		(iii) Sole power to dispose or to direct the disposition of:	0
		(iv) Shared power to dispose or to direct the disposition of:	0

Item 5. Ownership of Five Percent or Less of a Class.
	If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: [X]
Item 6. Ownership of More Than Five Percent on Behalf of Another Person.
	Not Applicable.
Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable.
Item 8. Identification and Classification of Members of the Group.
	Not Applicable.
Item 9. Notice of Dissolution of Group.
	Not Applicable.
Item 10. Certification.
	By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

	February 16, 2021

	NEWTYN MANAGEMENT, LLC


	By:	/s/ Eugene Dozortsev
		Name: Eugene Dozortsev
		Title: Authorized Signatory

Attention: Intentional misstatements or omissions of fact constitute

Federal criminal violations (See 18 U.S.C. 1001)

Get the next $FWP alert in real time by email

SEC Form SC 13G/A filed

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$FWP

SEC Form SC 13G/A filed

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$FWP

$FWP
Press Releases

Forward Pharma Announces Expected Delisting of its American Depositary Shares from the Nasdaq Capital Market

Forward Pharma Announces the Decision of the Enlarged Board of Appeal of the European Patent Office in the EP2801355 Petition for Review

Forward Pharma Reports Financial and Operating Results for the Year Ended December 31, 2021

$FWP
SEC Filings

SEC Form EFFECT filed by Forward Pharma A/S

SEC Form POS AM filed by Forward Pharma A/S

SEC Form S-8 POS filed by Forward Pharma A/S

$FWP
Large Ownership Changes